PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Yoichi Nagata(The University of Texas MD Anderson Cancer Center), Dihua Yu(The University of Texas MD Anderson Cancer Center), Ayşegül A. Şahin(The University of Texas MD Anderson Cancer Center), Kristine S. Klos(Minnesota Department of Health), Brett P. Monia(Ionis Pharmaceuticals (United States)), Mien‐Chie Hung(Precision Therapeutics (United States)), Francisco J. Esteva(Northwell Health), Ping Li(The University of Texas MD Anderson Cancer Center), Xiaoyan Zhou(Shanghai Medical College of Fudan University), Nina Nguyen(The University of Texas MD Anderson Cancer Center), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center), Keng‐Hsueh Lan(National Taiwan University), Ming Tan(USA Mitchell Cancer Institute)
Cited by 1,866
Related Papers
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
|Clinical Chemistry|2008|1.1k
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
|Nature Communications|2016|1.1k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k